Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Target price


24.07.24 / Tradegate WKN: 853260 / Symbol: JNJ / Name: Johnson & Johnson / Stock / Pharmaceuticals / Large Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.

Johnson & Johnson Stock

Johnson & Johnson gained 2.580% today.
The stock is one of the favorites of our community with 39 Buy predictions and 1 Sell predictions.
With a target price of 195 € there is a positive potential of 35.21% for Johnson & Johnson compared to the current price of 144.22 €.
So far the community has only identified positive things for Johnson & Johnson stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".

Johnson Johnson is a multinational company that focuses on the development, manufacturing, and marketing of a wide range of consumer health products, medical devices, and pharmaceuticals. The company was founded in 1886 and is headquartered in New Jersey, USA. It operates in more than 60 countries and has a diverse portfolio of popular brands including Band-Aid, Tylenol, and Neutrogena. As of 2021, Johnson Johnson has a market capitalization of over $435 billion and is listed on the New York Stock Exchange under the symbol JNJ.

Pros and Cons of Johnson & Johnson in the next few years

W********* I********* f** t** n*** y****
G***** c******* t* c**********
S********** s********
C******** o* t** e**********
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'

Performance of Johnson & Johnson vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
Johnson & Johnson 2.580% 0.740% 3.830% -6.774% 1.850% -1.179% 23.794%
Elanco Animal Health Inc. 1.580% -1.607% -30.491% 7.835% -13.062% -62.096% -
Biogen Inc. 0.970% -0.144% -1.185% -16.733% -11.578% -24.525% -3.828%
Pfizer Inc. 1.750% 0.765% 4.752% -18.392% 5.996% -21.894% -24.065%

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2023-11-14

Johnson & Johnson, symbolized as JNJ, holds a prominent position in the Pharmaceutical industry. Reviewing their financial data indicate robust financial base and promising trends over the years. Their capacity to generate revenues and maintain substantial margins underscores their operational efficiency. On the flip side, the high levels of liabilities and debts might raise some eyebrows. The analysis below explores these aspects in depth.

Reflecting upon the income statement for the years 2020, 2021 and 2022, it's clear that JNJ has shown consistent growth in net income. For instance, in 2022, the net income was listed at $17.94 billion compared to $14.71 billion in 2020. Not just the net income, even the gross profit has shown positive trends, increasing from $54.15 billion in 2020 to $63.85 billion in 2022, reinforcing their capacity to improve operational efficiency and drive profits.

The cash flow statements for the corresponding years paint a similar picture. The total cash from operating activities for 2022 was $21.19 billion as compared to $23.53 billion in 2020. While there was a slight drop, the numbers clearly indicate that Johnson & Johnson has maintained substantial cash flow from its main line of business.


Prediction Buy
Perf. (%) 0.87%
Target price 169.719
Ends at 19.07.25

Johnson & Johnson (NYSE: JNJ) had its price target lowered by analysts at TD Cowen from $195.00 to $185.00. They now have a "buy" rating on the stock.
Ratings data for JNJ provided by MarketBeat
Show more

Prediction Buy
Perf. (%) 4.83%
Target price 199.993
Ends at 01.07.25

Johnson & Johnson (NYSE: JNJ) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $215.00 price target on the stock.
Ratings data for JNJ provided by MarketBeat
Show more

Johnson & Johnson (NYSE: JNJ) was upgraded by analysts at from a "buy" rating to a "strong-buy" rating.
Ratings data for JNJ provided by MarketBeat
Show more